Outcomes of Renal Allograft Recipients With Hepatitis C
Outcomes of Renal Allograft Recipients With Hepatitis C
复制标题
DOI：
10.1016/j.transproceed.2016.02.050
复制
发表时间：
2016-04-01
影响因子：
0.9
通讯作者：
Que, E.
中科院分区：
文献类型：
--
作者：
Carpio, R.;Pamugas, G. E.;Que, E.
背景丙型肝炎病毒（HCV）感染的影响的研究表明，降低移植物存活率相比，HCV阴性匹配的患者。它也被确定为肾移植患者移植物丢失和死亡的独立危险因素。本研究旨在评估国家肾脏和移植研究所HCV感染的肾移植受者的10年移植物和患者结局。方法.这是一项回顾性研究的患者接受肾移植与HCV感染和一组谁是HCV阴性在同一移植后时期。资料来源于住院和门诊病历。HCV阳性组患者的生存率显著低于HCV阴性组。HCV阴性患者的平均生存期为154.95（+4.95）个月（12年零10个月），而HCV阳性组为141（+6.52）个月（11年零9个月）（P = 0.05）。移植物存活率在HCV阳性和HCV阴性受者之间没有显著差异（P = 0.734）。HCV阴性患者的平均移植物存活时间为137（+7.68）个月（11年5个月），而HCV阳性患者为130（+6.84）个月（10年10个月）。短期和长期结果包括活检证实的急性排斥反应、移植肾小球病、慢性移植物肾病、肾功能和蛋白尿在两组中相似。两组的排斥反应、肾小球病和肾功能相似。在移植前6个月可检测到HCV-RNA的患者中也观察到HCV进展。
Background. Studies on the effect of hepatitis C virus (HCV) infection showed decreased graft survival compared to HCV-negative matched patients. It was also identified as an independent risk factor for graft loss and mortality in kidney transplantation patients.Objective. This study was designed to evaluate the 10-year graft and patient outcomes of renal allograft recipients with HCV infection at the National Kidney and Transplant Institute. Methods. This is a retrospective study of patients who underwent renal transplantation with HCV infection and a group who were HCV-negative in the same post-transplantation period. Data were gathered from the in-patient and out-patient clinic records.Results. Patient survival was significantly lower in the HCV-positive than in the HCV-negative group. The mean duration of patient survival was 154.95 (+4.95) months (12 years and 10 months) in HCV-negative patients compared to 141 (+6.52) months (11 years and 9 months) in the HCV-positive group (P = .05). Graft survival did not differ significantly between HCV-positive and HCV-negative recipients (P = .734). The mean duration of graft survival was 137 (+7.68) months (11 years and 5 months) in HCV-negative patients compared to 130 (+6.84) months (10 years and 10 months) in HCV-positive patients. Short and long-term outcomes including biopsy-proven acute rejection, transplant glomerulopathy, chronic allograft nephropathy, renal function, and proteinuria were similar in both groups.Conclusion. Rejection, glomerulopathy, and renal function were similar in both groups. HCV progression was also observed in patients with detectable HCV-RNA 6 months before transplantation.